Brigatinib (AP-26113, Alunbrig) is a second-generation anaplastic lymphoma 
kinase (ALK) tyrosine kinase inhibitor (TKI) that is highly active in non-small 
cell lung cancer (NSCLC) harboring ALK translocation. Brigatinib was found to be 
very active against different ALK resistance mutations that mediate acquired 
resistance biology processes, particularly G1269A ALK C1156Y, I1171S/T, V1180L 
and others. Different clinical trials evaluated the activity of brigatinib in 
crizotinib-resistant patients, confirming high activity with durable response 
not only in parenchymal disease, but also in intracranial disease. Nowadays, 
brigatinib is under evaluation in different clinical trials exploring TKI-naive 
patients in the first-line setting. On the basis of its significant activity 
results, brigatinib received approval by the FDA for the treatment of patients 
with ALK-positive metastatic NSCLC who have progressed on or are intolerant to 
crizotinib.